When is colchicine indicated for the treatment of jaundice (e.g., cholestatic jaundice)?

Colchicine is NOT a standard or recommended treatment for jaundice

Colchicine should not be used to treat jaundice itself, but has been historically investigated (with limited evidence) for treating the underlying cholestatic liver diseases that cause jaundice, specifically primary biliary cirrhosis (PBC) and alcoholic cirrhosis—though it is NOT recommended in current guidelines.

Current Guideline-Based Treatment for Cholestatic Jaundice

The EASL 2009 guidelines for cholestatic liver diseases make no recommendation for colchicine in the management of cholestatic conditions 1. Instead:

For Primary Biliary Cirrhosis (PBC):

• Ursodeoxycholic acid (UDCA) at 13-15 mg/kg/day is the treatment of choice for PBC, not colchicine 1
• UDCA decreases serum bilirubin, alkaline phosphatase, and cholesterol levels while ameliorating histological features
• The guidelines mention corticosteroids (prednisolone, budesonide) as adjunctive therapy in combination with UDCA for early-stage PBC, but colchicine is conspicuously absent from treatment recommendations 1

For Primary Sclerosing Cholangitis (PSC):

• UDCA has been studied at various doses (10-30 mg/kg/day) with mixed results 1
• No mention of colchicine as a treatment option 1

Why Colchicine Is Not Recommended

While older research from the late 1980s-early 1990s suggested colchicine might improve survival in cirrhosis 2 and reduce mortality in cirrhotics 3, these findings:

1. Have not been incorporated into modern clinical practice guidelines
2. Were challenged by subsequent studies showing only marginal or statistically insignificant benefits 4
3. Lacked the quality and consistency needed to change practice standards

The FDA labeling for colchicine 5 indicates approved uses for:

• Familial Mediterranean Fever (FMF)
• Gout flares (prophylaxis and treatment)

Cholestatic liver disease or jaundice is NOT an FDA-approved indication, and the drug label notes variable pharmacokinetics in patients with primary biliary cirrhosis with "no consistent trends" 5.

Clinical Bottom Line

Do not use colchicine to treat jaundice. Instead:

1. Identify the cause of jaundice (cholestatic vs hepatocellular vs hemolytic)
2. For cholestatic jaundice from PBC: Use UDCA 13-15 mg/kg/day 1
3. For symptomatic management: Treat pruritus with cholestyramine, rifampicin, or naltrexone as first/second-line agents 6
4. Address complications: Monitor for osteoporosis, fat-soluble vitamin deficiencies, and nutritional status 6

Critical Caveat

One case report 7 described colchicine use in an elderly man with combined PBC and cholelithiasis, but this represents anecdotal experience, not evidence-based practice. The historical use of colchicine in cholestatic disease 8 has been superseded by UDCA and other evidence-based therapies.